Heartflow initiated with an Outperform at William Blair

William Blair initiated coverage of Heartflow (HTFL) with an Outperform rating and no piece target. The company’s AI-enabled, non-invasive platform changes the heart attack paradigm, providing actionable information without invasive tests, the analyst tells investors in a research note. The firm says Heartflow is already executing on trials to more than double its total addressable market with the estimated $6B opportunity in asymptomatic screening. As a pure pay-per-click, Heartflow has 80%-plus gross margins, adds the firm.